Recent studies on retatrutides, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, demonstrate promising findings in managing weight gain and type 2 diabetic condition. Early data from clinical trials point to considerable diminutions in body mass and improved glucose control. Further research is directed on long-term harmles